Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.36 |
| ▸ | CASP7 | P55210 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | AMY1A | P0DUB6 | 2/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.34 |
| ▸ | ALPL | P05186 | 1/20 | 0.33 |
| ▸ | ALPI | P09923 | 1/20 | 0.33 |
| ▸ | ALPG | P10696 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2610909 | 1.00 | KDM4E (0.55) | KDM4EKMT2AMAPTNPC1TP53 | |
| SCHEMBL30753425 | 0.87 | KDM4E (0.53) | KDM4EKMT2AMAPTNPC1TP53 | |
| SCHEMBL2136446 | 0.86 | KDM4E (0.51) | KDM4EKMT2AMAPTNPC1TP53 | |
| SCHEMBL10851061 | 0.82 | KDM4E (0.69) | KDM4EKMT2AMAPTNPC1TP53 | |
| SCHEMBL27428014 | 0.81 | NT5E (0.41) | KDM4EKMT2AMAPTCYP1A2CYP2C9 | |
| SCHEMBL16512406 | 0.81 | KDM4E (0.41) | KDM4EKMT2AMAPTSMN1; SMN2GAA | |
| SCHEMBL2131608 | 0.79 | MAPT (0.53) | KDM4EKMT2AMAPTNPC1CYP1A2 | |
| SCHEMBL2135136 | 0.79 | KDM4E (0.46) | KDM4EKMT2AMAPTNPC1TP53 | |
| SCHEMBL24188679 | 0.78 | MAPT (0.50) | KDM4EKMT2AMAPTNPC1CYP1A2 | |
| SCHEMBL15665255 | 0.77 | TDP1 (0.54) | KDM4EKMT2AMAPTNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9493506-B2 | Macrocyclic hepatitis C serine protease inhibitors | ABBVIE INC. (US) | 2016-11-15 | — | — | US | disclosed |
| US-9493506-B2 | Macrocyclic hepatitis C serine protease inhibitors | ABBVIE INC. (US) | 2016-11-15 | — | — | US | disclosed |
| US-9493506-B2 | Macrocyclic hepatitis C serine protease inhibitors | ABBVIE INC. (US) | 2016-11-15 | — | — | US | disclosed |
| US-20140287992-A1 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ABBOTT LABORATORIES | 2014-09-25 | — | — | US | disclosed |
| US-20140287992-A1 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ABBOTT LABORATORIES | 2014-09-25 | — | — | US | disclosed |
| US-20140287992-A1 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ABBOTT LABORATORIES | 2014-09-25 | — | — | US | disclosed |
| US-8748374-B2 | Macrocyclic hepatitis C serine protease inhibitors | ABBVIE, INC. (US) | 2014-06-10 | — | — | US | disclosed |
| US-8748374-B2 | Macrocyclic hepatitis C serine protease inhibitors | ABBVIE, INC. (US) | 2014-06-10 | — | — | US | disclosed |
| US-8748374-B2 | Macrocyclic hepatitis C serine protease inhibitors | ABBVIE, INC. (US) | 2014-06-10 | — | — | US | disclosed |
| EP-2576564-A2 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | Abbvie Inc. (US) | 2013-04-10 | — | — | EP | disclosed |
| CN-103025736-A | Macrocyclic hepatitis c serine protease inhibitors | ABBVIE INC | 2013-04-03 | — | — | CN | disclosed |
| US-20120101031-A1 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2012-04-26 | — | — | US | disclosed |
| US-20120101031-A1 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2012-04-26 | — | — | US | disclosed |
| US-20120101031-A1 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2012-04-26 | — | — | US | disclosed |
| WO-2011156337-A2 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ABBOTT LABORATORIES (US) | 2011-12-15 | — | — | WO | disclosed |
| WO-2011156337-A2 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ABBOTT LABORATORIES (US) | 2011-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101031-A1 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | TMPRSS15, PRSS1, SPINT2 | KDM4E 2948/4885KMT2A 4134/4885MAPT 3207/4885 |
| US-20140287992-A1 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | TMPRSS15, PRSS1, SPINT2 | KDM4E 2948/4885KMT2A 4134/4885MAPT 3207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.